BioAdaptives, Inc. (OTC: BDPT) has announced the upcoming commercial launch of XcellaraHeart™, a cardiovascular wellness supplement that combines the company’s Xcellara™ stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root. The product is scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected in early August.
The Xcellara™ base formula is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, with zero adverse effects on more than twenty blood parameters. Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair biology.
XcellaraHeart™ is designed around a two-part cardiovascular wellness strategy: stem/progenitor cell mobilization combined with cardiovascular signaling support. A scientific evidence dossier detailing the formulation is available on the company’s product website at products.xcellara.com/science. The dossier separates findings from BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and the company’s product-development rationale for combining the two.
BioAdaptives is the developer of the Xcellara™ line of stem cell mobilization and tissue-homing supplements. The product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. More information can be found at products.xcellara.com.
The launch of XcellaraHeart™ represents a significant step in BioAdaptives’ strategy to address cardiovascular health through a novel approach that leverages the body’s own repair mechanisms. By combining a clinically validated stem cell mobilizer with a compound that supports cardiovascular signaling, the company aims to offer a differentiated product in the dietary supplement market. The availability of a scientific evidence dossier underscores BioAdaptives’ commitment to transparency and evidence-based product development.
